Singapore wound care products manufacturer Cuprina (CUPR.US) has applied to be listed in the United States, with plans to raise $16 million.

Singapore-based skincare and chronic wound care product provider Cuprina Holdings announced the terms of its initial public offering (IPO) on Tuesday. The company plans to issue 3.8 million shares of stock at a price of $4-4.5 per share to raise $16 million. Cuprina Holdings plans to list on Nasdaq under the stock symbol "CUPR". It is reported that Cuprina Holdings focuses on the development and commercialization of chronic wound care products, and intends to expand its business to pharmaceutical products in the future. The company currently produces and sells a range of medical-grade sterile maggot bio-dressing products under the brand MEDIFLY. In addition to the MEDIFLY products, the company also has two chronic wound care product production lines in development, with development expected to take place in 2024 and 2025. Since 2020, Cuprina has mainly sold MEDIFLY products in Singapore and plans to enter Hong Kong, China in 2023. The company plans to further expand into the Southeast Asia, Middle East, and Mainland China markets in 2024 and 2025.